Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Jonathan M. Ducore, MD MPH, Shadan Lalezari, PhD, Elena Santagostino, MD PhD, Sanjay P Ahuja, MD, Monika Maas Enriquez, Claudia Tueckmantel, PhD, Mark Reding

Blood (2019) 134 (Supplement_1): 1129.

https://doi.org/10.1182/blood-2019-123947

Published: 2019

Journal Articles

Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures

Blood (2018) 132 (Supplement 1): 3774.

https://doi.org/10.1182/blood-2018-99-115979

Published: 2018

Journal Articles

Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94-9027) Study

Elena Santagostino, MD PhD, Bryce A. Kerlin, MD, Claude Negrier, Liu Tian, Dr, Jonathan M. Ducore, MD

Blood (2018) 132 (Supplement 1): 2486.

https://doi.org/10.1182/blood-2018-99-116031

Published: 2018

Journal Articles

Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)

Birgit M Reipert, PhD, Bagirath Gangadharan, PhD, Christoph J Hofbauer, PhD, Fritz Scheiflinger, PhD, Joel Bowen, Elizabeth Donnachie, PhD, Karen Fijvandraat, MD, Ralph A. Gruppo, MD, Jenny Klintman, MD PhD, Christoph Male, MD, Catherine E. McGuinn, MD, Shannon L. Meeks, MD, Michael Recht, MD PhD, M V Ragni, MD, Hassan M Yaish, Elena Santagostino, MD PhD, Deborah L Brown, MD

Blood (2016) 128 (22): 328.

https://doi.org/10.1182/blood.V128.22.328.328

Published: 2016

Journal Articles

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Blood (2016) 128 (22): 3774.

https://doi.org/10.1182/blood.V128.22.3774.3774

Published: 2016

Journal Articles

Safety and Efficacy of Turoctocog Alfa in Prevention and on-Demand Treatment of Bleeding Episodes in Patients with Hemophilia A

Dragana Janic, MD PhD, Irina Matytsina, MD, Mudi Misgav, Johannes Oldenburg, Prof, Margareth C Ozelo, Michael Recht, MD PhD, Lars Korsholm, Aleksandar Savic, Elena Santagostino, MD PhD

Blood (2016) 128 (22): 3790.

https://doi.org/10.1182/blood.V128.22.3790.3790

Published: 2016

Journal Articles

Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study

Johnny Mahlangu, Johannes Oldenburg, Prof, Michael U Callaghan, MD, Midori Shima, MD PhD, Elena Santagostino, MD PhD, Michaela Lehle, PhD, Marianne Uguen, MSc, Ceri Hirst, PhD, Maggie Moore, RN, Michael Recht, MD PhD, Claudia Garcia, MD, Renchi Yang, MD PhD, Rebecca Kruse-Jarres, MD MPH

Blood (2016) 128 (22): 3800.

https://doi.org/10.1182/blood.V128.22.3800.3800

Published: 2016

Journal Articles

Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

Aaron Lubetsky, MD, Uri Martinowitz, MD, Toshko Lissitchkov, MD, Christine Voigt, PhD, Denise Wolko, Iris C. Jacobs, MD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 1096.

https://doi.org/10.1182/blood.V126.23.1096.1096

Published: 2015

Journal Articles

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Claude Negrier, MD, Lynda Mae Lepatan, MD, Faralzah Karim, MD, Anne Lienhart, MD, Denise Wolko, Christine Voigt, PhD, Iris C. Jacobs, MD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 2298.

https://doi.org/10.1182/blood.V126.23.2298.2298

Published: 2015

Journal Articles

Successful Use of rFVIII, Turoctocog Alfa, during Orthopedic and Nonorthopedic Surgery in Patients with Severe Hemophilia A

Luigi Solimeno, MD, Steven R. Lentz, MD PhD, Irina Matytsina, MD, Niels Zeuthen, Faraizah Abdul Karim, MD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 2304.

https://doi.org/10.1182/blood.V126.23.2304.2304

Published: 2015

Journal Articles

Long-Term Follow-up of Hemophilia a Patients Who Previously Showed Complete or Partial Success in Immune Tolerance Induction Therapy with a Single Plasma-Derived FVIII/VWF Product: Long-Term ITI Study

Víctor Jiménez-Yuste, Dr, Johannes Oldenburg, MD PhD, Savita Rangarajan, MBBS, FRCP, FRCPath, Roser Peiró, PhD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 2282.

https://doi.org/10.1182/blood.V126.23.2282.2282

Published: 2015

Journal Articles

First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a

Kingsley Hampton, Pratima Chowdary, Scott Dunkley, Silke Ehrenforth, MD PhD, Lotte Jacobsen, Anne T. Neff, MD, Elena Santagostino, MD PhD, Jameela Sathar, Hideyuki Takedani, Clifford M. Takemoto, MD, Claude Négrier

Blood (2015) 126 (23): 2283.

https://doi.org/10.1182/blood.V126.23.2283.2283

Published: 2015

Journal Articles

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Flora Peyvandi, MD PhD, Pier Mannuccio Mannucci, MD, Isabella Garagiola, PhD, Mohsen Elalfy, MD, Amal El-Beshlawy, MD, Madatha V. Ramanan, MD, Peyman Eshghi, MD, Suresh Hanagavadi, Ramabadran Varadarajan, MD, Mehran Karimi, MD, Mamta V. Manglani, MD, Cecil Ross, MD, Guy Young, MD, Tulika Seth, MD, Shashikant Apte, MD FRCPA, Dinesh M. Nayak, MD, Adriana C. Sandoval Gonzales, MD, Elena Santagostino, MD PhD, Maria Elisa Mancuso, MD PhD, Johnny N. Mahlangu, MD, Santiago Bonanad, PhD, Monica Cerqueira, MD, Nadia P. Ewing, MD, Christoph Male, MD MSC, Tarek Owaidah, MD FRCPA, Veronica Soto Arellano, MD, Nathan L. Kobrinsky, MD FRCP, Suvankar Majumdar, MD, Rosario Perez Garrido, MD, Anupam Sachdeva, Mindy Simpson, MD FAAP, Mathew Thomas, Ezio Zanon, MD, ALI Bulent Antmen, Kaan Kavakli, MD, Marilyn Manco-Johnson, MD, Monica Martinez, MD, Esperanza Marzouka, MS, PS, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Angeles Palomo Bravo, MD, Rogelio Paredes Aguilera, MD, Alessandra Nunes Loureiro Prezotti, MD, Schmitt Klaus, MD, Brian M. Wicklund, MD MPH, Bulent Zulfikar, MD, Rosendaal R. Frits, MD PhD

Blood (2015) 126 (23): 5.

https://doi.org/10.1182/blood.V126.23.5.5

Published: 2015

Journal Articles

Rviii-Singlechain in Surgical Prophylaxis: Efficacy and Safety of Continuous and Bolus Infusion

Claudia Djambas Khayat, MD BS, Johnny N. Mahlangu, MD, Ross I Baker, MD, Cindy A. Leissinger, MD, Elena Santagostino, MD PhD, Debra M. Bensen-Kennedy, MD, Katie St. Ledger, MS, Alex Veldman, MD, Ingrid Pabinger, MD

Blood (2015) 126 (23): 3525.

https://doi.org/10.1182/blood.V126.23.3525.3525

Published: 2015

Journal Articles

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

Manuel Carcao, MD, Maria L. Avila, MD, Victor S. Blanchette, MD FRCP, Elena Santagostino, MD PhD, Carmen Escuriola-Ettingshausen, MD PhD, Cindy A. Leissinger, MD, Thierry Lambert, Louis M. Aledort, MD

Blood (2015) 126 (23): 3535.

https://doi.org/10.1182/blood.V126.23.3535.3535

Published: 2015

Journal Articles

Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B

Elena Santagostino, MD PhD, Christine Voigt, PhD, Denise Wolko, Grace Cole, Yanyan Li, PhD, Iris C. Jacobs, MD

Blood (2015) 126 (23): 548.

https://doi.org/10.1182/blood.V126.23.548.548

Published: 2015

Journal Articles

Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype

Maria Elisa Mancuso, MD PhD, Maria Rosaria Fasulo, MD, Antonino Cannavò, MD, Flora Peyvandi, MD PhD, Elena Santagostino, MD PhD

Blood (2014) 124 (21): 2844.

https://doi.org/10.1182/blood.V124.21.2844.2844

Published: 2014

Journal Articles

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

Guy Young, MD, Peter W. Collins, MD, Ramin Tehranchi, MD, PhD, Ampaiwan Chuansumrit, Hideji Hanabusa, MD, Steven R. Lentz, MD PhD, Johnny N. Mahlangu, MBBCh, MMed, FCPath, Evelien Mauser-Bunschoten, Claude Negrier, Johannes Oldenburg, MD PhD, Turkan Patiroglu, MD, Elena Santagostino, MD PhD, Marek Zak, Fara Abdul Karim

Blood (2014) 124 (21): 2846.

https://doi.org/10.1182/blood.V124.21.2846.2846

Published: 2014

Journal Articles

Safety, Efficacy and Pharmacokinetics of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Pediatric Hemophilia B Patients

Manuel Carcao, MD MSc, Marek Zak, Fara Abdul Karim, Hideji Hanabusa, MD, Susan Kearney, Meng-Yao Lu, Paula Persson, Savita Rangarajan, Elena Santagostino, MD PhD

Blood (2014) 124 (21): 1513.

https://doi.org/10.1182/blood.V124.21.1513.1513

Published: 2014

Journal Articles

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

Elena Santagostino, MD PhD, Iris C. Jacobs, MD, Christine Voigt, PhD, Annettee Feussner, PhD, Tharin Limsakun, PhD

Blood (2014) 124 (21): 1491.

https://doi.org/10.1182/blood.V124.21.1491.1491

Published: 2014

NARROW

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures

Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94-9027) Study

Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Safety and Efficacy of Turoctocog Alfa in Prevention and on-Demand Treatment of Bleeding Episodes in Patients with Hemophilia A

Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study

Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Successful Use of rFVIII, Turoctocog Alfa, during Orthopedic and Nonorthopedic Surgery in Patients with Severe Hemophilia A

Long-Term Follow-up of Hemophilia a Patients Who Previously Showed Complete or Partial Success in Immune Tolerance Induction Therapy with a Single Plasma-Derived FVIII/VWF Product: Long-Term ITI Study

First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Rviii-Singlechain in Surgical Prophylaxis: Efficacy and Safety of Continuous and Bolus Infusion

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B

Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

Safety, Efficacy and Pharmacokinetics of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Pediatric Hemophilia B Patients

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only